Ishtiaq Rehman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ishtiaq Rehman has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Leiblich
Department of Urology Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK
1 shared publication Alicia E. Wooding
1 shared publication- Freddie C. Hamdy
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
1 shared publication - Hing Y. Leung
CRUK Beatson Institute
1 shared publication J. Phillips
Sheffield University, Sheffield, United Kingdom
1 shared publicationJ.W.F. Catto
Sheffield University, Sheffield, United Kingdom
1 shared publication
Latest Publications
- 1 June 2014
- Published by Elsevier in e-SPEN Journal
- Vol. 9 (3) , e123-e130
Obesity and prostate cancer: Is there a link?
- 1 June 2014
- Published by Elsevier in e-SPEN Journal
- Vol. 9 (3) , e123-e130
Obesity and prostate cancer: Is there a link?
- Open Access
- 15 February 2006
- Published by Wiley in BJU International
- Vol. 97 (s1) , 6
21 Lactate dehydrogenase‐B is silenced by promoter hypermethylation in human prostate cancer
In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic profile of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP‐LN3, by two‐dimensional gel electrophoresis. A major protein spot (pI of 5.9 and molecular weight of 37 KDa) was seen in LNCaP cells, but not in LNCaP‐LN3 cells and was identified as Lactate dehydrogenase‐B ( LDHB ), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and Zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP‐LN3. Bisulfite modified DNA sequencing showed promoter hypermethylation in LNCaP‐LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP‐LN3 cells with 5’‐azacytidine caused re‐expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer 14/31 (45%), compared to adjacent non‐malignant or benign tissue, 2/19 (11%), ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or non‐malignant tissues, 59/ 73 (81%), compared to cancer cases, 3/53 (6%), ( P < 0.001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.
- 15 February 2006
- Published by Wiley in BJU International
- Vol. 97 (s1) , 6
Open Access21 Lactate dehydrogenase‐B is silenced by promoter hypermethylation in human prostate cancer
In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic profile of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP‐LN3, by two‐dimensional gel electrophoresis. A major protein spot (pI of 5.9 and molecular weight of 37 KDa) was seen in LNCaP cells, but not in LNCaP‐LN3 cells and was identified as Lactate dehydrogenase‐B ( LDHB ), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and Zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP‐LN3. Bisulfite modified DNA sequencing showed promoter hypermethylation in LNCaP‐LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP‐LN3 cells with 5’‐azacytidine caused re‐expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer 14/31 (45%), compared to adjacent non‐malignant or benign tissue, 2/19 (11%), ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or non‐malignant tissues, 59/ 73 (81%), compared to cancer cases, 3/53 (6%), ( P < 0.001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.